SERC (betahistine) is a medication that can treat episodes of recurrent vertigo that are associated with Ménière’s disease. People with Ménière’s disease have extra fluid that builds inside of their ear canals. Extra fluid interferes with the nerves in the inner ear that detect position, movement, and balance. People with Ménière’s disease have recurrent episodes of vertigo that may interfere with their daily lives. SERC medication works by interacting with both histamine-1 and histamine-3 receptors on the surface of nerve cells of the ear. The interactions seem to decrease how much histamine is available to activate these nerve cells. SERC also increases blood flow to the inner ear and it slows down nerve signals in lateral and medial vestibular nuclei. The FDA has not approved SERC for any indication in the United States. SERC is widely used in both Europe and Canada.